William Blair Has Bearish Forecast for BMY FY2026 Earnings
Equities research analysts at William Blair decreased their FY2026 earnings per share estimates for shares of Bristol-Myers ...
Hosted on MSN19h
William Blair Initiates Coverage of Rubrik (RBRK) with Market Perform Recommendation
Fintel reports that on February 7, 2025, William Blair initiated coverage of Rubrik (NYSE:RBRK) with a Market Perform ...
William Blair Has Bullish Forecast for MOD FY2025 Earnings
Equities research analysts at William Blair upped their FY2025 EPS estimates for shares of Modine Manufacturing in a note ...
Why Is Neurocrine Biosciences Stock Trading Lower On Friday?
Neurocrine Biosciences Q4 earnings topped forecasts, but revenue slightly missed. Analysts see Ingrezza's long-term growth ...
BioSpace22h
FDA Approval of Vertex’s Non-Opioid Journavx Signals New Era in Pain Treatment
If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...
medtechdive21h
BD plans split from life science business to fuel medtech investment
CEO Tom Polen said BD will “double down on shifting our portfolio, both organically and inorganically through tuck-in M&A, ...
Williamsburg-area school board might consider changing name of James Blair Middle School
WJCC Schools last changed the name of one of its schools in 2017. Before it was Laurel Lane Elementary, the elementary school ...
Dayforce Inc (DAY) Among the Best Human Resources Stocks to Invest In
We recently published a list of 10 Best Human Resources Stocks To Invest In. In this article, we are going to take a look at ...
American Banker18h
Affirm's 0% loans, cards, chart a path to profitability
The buy now/pay later lender outperformed nearly every analyst estimate in its fiscal Q2 2025 earnings report. CEO Max Levchin said the company is 5 months out from positive GAAP operating income.